{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:17:57Z","timestamp":1769062677449,"version":"3.49.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ymgme.2023.107693","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T15:56:05Z","timestamp":1693410965000},"page":"107693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The treatment of biochemical genetic diseases: From substrate reduction to nucleic acid therapies"],"prefix":"10.1016","volume":"140","author":[{"given":"E. Naomi","family":"Vos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didem","family":"Demirbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Mangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Estela","family":"Rubio-Gozalbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey L.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard T.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jimd.12348","article-title":"An international classification of inherited metabolic disorders (ICIMD)","volume":"44","author":"Ferreira","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/MOP.0000000000001168","article-title":"Advancements in therapeutics for inborn errors of metabolism","volume":"34","author":"Turner","year":"2022","journal-title":"Curr. Opin. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/ETLS20180058","article-title":"Substrate reduction therapy for inborn errors of metabolism","volume":"3","author":"Yue","year":"2019","journal-title":"Emerg. Top. Life Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10545-016-9979-0","article-title":"Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency","volume":"40","author":"Morris","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107693_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17071065","article-title":"Less is more: substrate reduction therapy for lysosomal storage disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0014-5793(93)80013-K","article-title":"SC-0051, a 2-benzoyl-cyclohexane-1,3-dione bleaching herbicide, is a potent inhibitor of the enzyme p-hydroxyphenylpyruvate dioxygenase","volume":"318","author":"Schulz","year":"1993","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/taap.1995.1121","article-title":"Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione","volume":"133","author":"Ellis","year":"1995","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ymgme.2023.107693_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/TACG.S113310","article-title":"Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)","volume":"10","author":"Das","year":"2017","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymgme.2023.107693_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13023-014-0107-7","article-title":"Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice","volume":"9","author":"Mayorandan","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13023-021-01977-0","article-title":"Preventive use of nitisinone in alkaptonuria","volume":"16","author":"Wolffenbuttel","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107693_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-7-32","article-title":"Suggested guidelines for the diagnosis and management of urea cycle disorders","volume":"7","author":"H\u00e4berle","year":"2012","journal-title":"Orphanet. J. Rare Dis."},{"issue":"23","key":"10.1016\/j.ymgme.2023.107693_bb0060","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJM198206103062303","article-title":"Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion","volume":"306","author":"Batshaw","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2023.107693_bb0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1750-1172-7-68","article-title":"Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management","volume":"7","author":"Magoulas","year":"2012","journal-title":"Orphanet. J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0070","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jimd.12241","article-title":"Consensus guideline for the diagnosis and management of mannose phosphate isomerase-congenital disorder of glycosylation","volume":"43","author":"\u010cechov\u00e1","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"19","key":"10.1016\/j.ymgme.2023.107693_bb0075","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM197411072911901","article-title":"Replacement therapy for inherited enzyme deficiency","volume":"291","author":"Brady","year":"1974","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jgg.2018.02.001","volume":"45","author":"Gambello","year":"2018","journal-title":"J. Genet. Genom."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14740\/jocmr4843","article-title":"Current and novel therapeutical approaches of classical homocystinuria in childhood with special focus on enzyme replacement therapy, liver-directed therapy and gene therapy","volume":"15","author":"Bittmann","year":"2023","journal-title":"J. Clin. Med. Res."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0100","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgme.2023.107693_bb0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13023-014-0130-8","article-title":"Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia","volume":"9","author":"Baumgartner","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5582\/irdr.2018.01026","article-title":"Methylmalonic acidemia: current status and research priorities","volume":"7","author":"Zhou","year":"2018","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.ymgme.2023.107693_bb0115","first-page":"127","article-title":"Biotinidase deficiency: prevalence, impact and management strategies","volume":"11","author":"Canda","year":"2020","journal-title":"Pediatric. Health. Med. Ther."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0120","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1203\/00006450-197009000-00081","article-title":"Vitamin B6 responsive Homocystinuria","volume":"4","author":"Seashore","year":"1970","journal-title":"Pediatr. Res."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41436-019-0647-2","article-title":"Therapeutic approaches in congenital disorders of glycosylation (CDG) involving N-linked glycosylation: an update","volume":"22","author":"Verheijen","year":"2020","journal-title":"Genet Med."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031887","article-title":"Chaperone therapy in Fabry disease","volume":"23","author":"Weidemann","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020489","article-title":"Pharmacological chaperones: a therapeutic approach for diseases caused by destabilizing missense mutations","volume":"21","author":"Liguori","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.107693_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2019.00433","article-title":"Hematopoietic stem cell transplantation in inborn errors of metabolism. Mini review","volume":"7","author":"Tan","year":"2019","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymgme.2023.107693_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.764626","article-title":"National U.S. Patient and transplant data for Krabbe disease","volume":"9","author":"Ghabash","year":"2021","journal-title":"Front. Pediatr."},{"issue":"13","key":"10.1016\/j.ymgme.2023.107693_bb0150","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107693_bb0155","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow. Transp."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0160","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1007\/s12325-020-01305-1","article-title":"Post-transplantation outcomes in patients with PA or MMA: a review of the literature","volume":"37","author":"Yap","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymgme.2023.107693_bb0165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fped.2019.00087","article-title":"The value of liver transplantation for Methylmalonic Acidemia","volume":"7","author":"Jiang","year":"2019","journal-title":"Front. Pediatr."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.01.051","article-title":"Treatment of methylmalonic acidemia by liver or combined liver-kidney transplantation","volume":"166","author":"Niemi","year":"2015","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ekir.2021.11.006","article-title":"Long-term transplantation outcomes in patients with primary hyperoxaluria type 1 included in the European hyperoxaluria consortium (OxalEurope) registry","volume":"7","author":"Metry","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymgme.2023.107693_bb0180","doi-asserted-by":"crossref","first-page":"1103757","DOI":"10.3389\/fped.2023.1103757","article-title":"Urea cycle disorders and indications for liver transplantation","volume":"11","author":"Garc\u00eda Vega","year":"2023","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-020-01391-y","article-title":"PKU dietary handbook to accompany PKU guidelines","volume":"15","author":"MacDonald","year":"2020","journal-title":"Orphanet. J. Rare Dis."},{"issue":"6790","key":"10.1016\/j.ymgme.2023.107693_bb0190","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(53)90473-5","article-title":"Influence of phenylalanine intake on phenylketonuria","volume":"265","author":"Bickel","year":"1953","journal-title":"Lancet."},{"key":"10.1016\/j.ymgme.2023.107693_bb0195","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1542\/peds.32.3.338","article-title":"A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants","volume":"32","author":"Guthrie","year":"1963","journal-title":"Pediatrics."},{"issue":"9750","key":"10.1016\/j.ymgme.2023.107693_bb0200","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0205","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","article-title":"The complete European guidelines on phenylketonuria: diagnosis and treatment","volume":"12","author":"van Wegberg","year":"2017","journal-title":"Orphanet. J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0215","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/A:1020158631102","article-title":"Phenylketonuria in adulthood: a collaborative study","volume":"25","author":"Koch","year":"2002","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/IJAMH.2004.16.1.41","article-title":"Blood phenylalanine control in adolescents with phenylketonuria","volume":"16","author":"Walter","year":"2004","journal-title":"Int. J. Adolesc. Med. Health."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107579","article-title":"Neuropsychological assessment of adults with phenylketonuria using the NIH toolbox","volume":"139","author":"Christ","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10519-017-9863-1","article-title":"Long-term follow-up of cognition and mental health in adult phenylketonuria: a PKU-COBESO study","volume":"47","author":"Jahja","year":"2017","journal-title":"Behav. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0235","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1037\/neu0000625","article-title":"Executive function in phenylketonuria (PKU): insights from the behavior rating inventory of executive function (BRIEF) and a large sample of individuals with PKU","volume":"34","author":"Christ","year":"2020","journal-title":"Neuropsychology."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0240","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/B:BOLI.0000028725.37345.62","article-title":"Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria","volume":"27","author":"Arnold","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107693_bb0245","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1037\/neu0000758","article-title":"Motor control and learning in individuals with early-treated phenylketonuria","volume":"35","author":"Christ","year":"2021","journal-title":"Neuropsychology."},{"issue":"23","key":"10.1016\/j.ymgme.2023.107693_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/nu14234960","article-title":"Complications of the low phenylalanine diet for patients with phenylketonuria and the benefits of increased natural protein","volume":"14","author":"McWhorter","year":"2022","journal-title":"Nutrients."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0275","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-3476(99)70138-1","article-title":"Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency","volume":"135","author":"Kure","year":"1999","journal-title":"J. Pediatr."},{"issue":"9586","key":"10.1016\/j.ymgme.2023.107693_bb0280","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2023.107693_bb0285","first-page":"231","article-title":"New era in treatment for phenylketonuria: pharmacologic therapy with sapropterin dihydrochloride","volume":"4","author":"Harding","year":"2010","journal-title":"Biologics."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0290","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2011.03.020","article-title":"Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"22","key":"10.1016\/j.ymgme.2023.107693_bb0300","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1002\/ajmg.a.32562","article-title":"Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria","volume":"146a","author":"Lee","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2023.107693_bb0305","first-page":"35","article-title":"The Kuvan(\u00ae) adult maternal paediatric European registry (KAMPER) multinational observational study: baseline and 1-year data in phenylketonuria patients responsive to sapropterin","volume":"23","author":"Trefz","year":"2015","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0310","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ymgme.2015.02.003","article-title":"Long-term safety and efficacy of sapropterin: the PKUDOS registry experience","volume":"114","author":"Longo","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0315","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jpeds.2010.08.016","article-title":"Tetrahydrobiopterin therapy for phenylketonuria in infants and young children","volume":"158","author":"Burton","year":"2011","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0320","first-page":"213","article-title":"Sapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four","volume":"57","author":"\u00dcnal","year":"2015","journal-title":"Turk. J. Pediatr."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0325","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10545-012-9464-3","article-title":"Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria","volume":"35","author":"Leuret","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0330","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jpeds.2014.08.003","article-title":"Sapropterin is safe and effective in patients less than 4-years-old with BH4-responsive phenylalanine hydrolase deficiency","volume":"165","author":"Shintaku","year":"2014","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-017-0600-x","article-title":"Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial","volume":"12","author":"Muntau","year":"2017","journal-title":"Orphanet. J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0340","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13023-021-01968-1","article-title":"Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial","volume":"16","author":"Muntau","year":"2021","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107693_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008005.pub2","article-title":"Sapropterin dihydrochloride for phenylketonuria","volume":"6","author":"Somaraju","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0350","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ymgme.2019.09.004","article-title":"Phenylalanine hydroxylase genotype-phenotype associations in the United States: a single center study","volume":"128","author":"Rajabi","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0355","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jpeds.2007.02.017","article-title":"Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria","volume":"150","author":"Fiege","year":"2007","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.107693_bb0360","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13023-015-0375-x","article-title":"Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness","volume":"10","author":"Jeannesson-Thivisol","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0365","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ymgme.2011.10.014","article-title":"START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients","volume":"105","author":"Utz","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0370","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ymgme.2007.09.017","article-title":"Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment","volume":"92","author":"Levy","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0375","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2012.04.004","article-title":"Recommendations for the use of sapropterin in phenylketonuria","volume":"106","author":"Cunningham","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107693_bb0380","first-page":"59","article-title":"Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response?","volume":"5","author":"Sarkissian","year":"2012","journal-title":"JIMD Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0385","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/humu.20097","article-title":"Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations","volume":"24","author":"Pey","year":"2004","journal-title":"Hum. Mutat."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107693_bb0390","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM198011203032104","article-title":"Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies","volume":"303","author":"Lenke","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0395","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ymgme.2014.02.016","article-title":"Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry","volume":"112","author":"Grange","year":"2014","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0400","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10545-014-9716-5","article-title":"Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases","volume":"37","author":"Feillet","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.107693_bb0405","article-title":"First Japanese case of maternal phenylketonuria treated with sapropterin dihydrochloride and the normal growth and development of the child","volume":"21","author":"Nyuzuki","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107693_bb0410","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/ped.13678","article-title":"Successful control of maternal phenylketonuria by tetrahydrobiopterin","volume":"60","author":"Sakamoto","year":"2018","journal-title":"Pediatr. Int."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0415","doi-asserted-by":"crossref","first-page":"e1881","DOI":"10.1542\/peds.2012-3291","article-title":"Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study","volume":"131","author":"Keil","year":"2013","journal-title":"Pediatrics."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0420","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/gim.2014.109","article-title":"Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy","volume":"17","author":"Longo","year":"2015","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0425","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ymgme.2014.11.014","article-title":"Individualized long-term outcomes in blood phenylalanine concentrations and dietary phenylalanine tolerance in 11 patients with primary phenylalanine hydroxylase (PAH) deficiency treated with Sapropterin-dihydrochloride","volume":"114","author":"Stockler-Ipsiroglu","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0430","doi-asserted-by":"crossref","DOI":"10.1111\/ped.14939","article-title":"Sapropterin for phenylketonuria: a Japanese post-marketing surveillance study","volume":"64","author":"Tamura","year":"2022","journal-title":"Pediatr. Int."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0435","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2014.10.013","article-title":"Adherence to tetrahydrobiopterin therapy in patients with phenylketonuria","volume":"114","author":"Rohr","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0440","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymgme.2021.01.001","article-title":"Long-term preservation of intellectual functioning in sapropterin-treated infants and young children with phenylketonuria: a seven-year analysis","volume":"132","author":"Waisbren","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jimd.12151","article-title":"Tetrahydrobiopterin treatment in phenylketonuria: a repurposing approach","volume":"43","author":"Evers","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.107693_bb0450","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nicl.2013.08.012","article-title":"The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria","volume":"3","author":"Christ","year":"2013","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.ymgme.2023.107693_bb0455","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/1477-7525-11-218","article-title":"Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride","volume":"11","author":"Douglas","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0460","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apa.13799","article-title":"Sapropterin treatment does not enhance the health-related quality of life of patients with phenylketonuria and their parents","volume":"106","author":"Feldmann","year":"2017","journal-title":"Acta Paediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0465","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1017\/S1092852914000455","article-title":"Pilot study to evaluate the effects of tetrahydrobiopterin on adult individuals with phenylketonuria with measurable maladaptive behaviors","volume":"20","author":"Moseley","year":"2015","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ymgme.2023.107693_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.155116","article-title":"PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study","volume":"128","author":"Bratkovic","year":"2022","journal-title":"Metabolism."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0475","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ymgme.2018.06.002","article-title":"Phenylalanine ammonia lyase (PAL): from discovery to enzyme substitution therapy for phenylketonuria","volume":"124","author":"Levy","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"8165","key":"10.1016\/j.ymgme.2023.107693_bb0480","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(80)90944-7","article-title":"Enzymatic control of phenylalanine intake in phenylketonuria","volume":"1","author":"Hoskins","year":"1980","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0485","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/10731199509117980","article-title":"Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report","volume":"23","author":"Safos","year":"1995","journal-title":"Artif. Cells Blood Substit. Immobil. Biotechnol."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0490","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1073\/pnas.96.5.2339","article-title":"A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase","volume":"96","author":"Sarkissian","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0495","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ymgme.2018.06.010","article-title":"Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria","volume":"125","author":"Zori","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0500","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2018.03.003","article-title":"Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation phase 3 clinical trial","volume":"124","author":"Harding","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0505","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0510","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/03007995.2018.1528215","article-title":"Pegvaliase: a novel treatment option for adults with phenylketonuria","volume":"35","author":"Mahan","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107693_bb0515","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2019.07.018","article-title":"Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria","volume":"128","author":"Zori","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107693_bb0520","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2019.05.006","article-title":"Pegvaliase: immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy","volume":"128","author":"Hausmann","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0530","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymgme.2021.05.006","article-title":"Palynziq clinic: one year and 43 patients later","volume":"133","author":"Lah","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107693_bb0535","article-title":"Continuation of pegvaliase treatment during pregnancy: a case report","volume":"26","author":"Boyer","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107693_bb0540","article-title":"Reinstitution of pegvaliase therapy during lactation","volume":"33","author":"Rohr","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107693_bb0545","article-title":"First 1.5 years of pegvaliase clinic: experiences and outcomes","volume":"24","author":"Sacharow","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107564","article-title":"Two years of pegvaliase in Germany: experiences and best practice recommendations","volume":"139","author":"Kr\u00e4mer","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107693_bb0555","article-title":"Use of pegvaliase in the management of phenylketonuria: case series of early experience in US clinics","volume":"28","author":"Adams","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107693_bb0560","article-title":"Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: evidence from dispensing data","volume":"33","author":"Lah","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107693_bb0565","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2022.08.001","article-title":"Pegvaliase dosing in adults with PKU: requisite dose for efficacy decreases over time","volume":"137","author":"Hollander","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107693_bb0570","article-title":"Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower doses","volume":"32","author":"Vucko","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0575","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ymgme.2021.06.002","article-title":"Nutrition status of adults with phenylketonuria treated with pegvaliase","volume":"133","author":"Viau","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/nu12041092","article-title":"Large Neutral Amino Acids (LNAAs) Supplementation Improves Neuropsychological Performances in Adult Patients with Phenylketonuria","volume":"12","author":"Scala","year":"2020","journal-title":"Nutrients."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0585","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ejcn.2016.166","article-title":"Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids","volume":"71","author":"Concolino","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0590","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymgme.2007.02.002","article-title":"The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study","volume":"91","author":"Schindeler","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107693_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/nu11102541","article-title":"Large neutral amino acid therapy increases tyrosine levels in adult patients with phenylketonuria: a long-term study","volume":"11","author":"Burlina","year":"2019","journal-title":"Nutrients."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0600","doi-asserted-by":"crossref","DOI":"10.1093\/synbio\/ysac001","article-title":"Development of synthetic biotics as treatment for human diseases","volume":"7","author":"Brennan","year":"2022","journal-title":"Synth. Biol."},{"key":"10.1016\/j.ymgme.2023.107693_bb0605","article-title":"State-of-the-Art 2023 on gene therapy for phenylketonuria","author":"Martinez","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0610","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107693_bb0615","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells."},{"key":"10.1016\/j.ymgme.2023.107693_bb0625","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.omtm.2022.09.002","article-title":"Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model","volume":"27","author":"Song","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2023.107693_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Front. Immunol."},{"issue":"13\u201314","key":"10.1016\/j.ymgme.2023.107693_bb0635","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of Myotubular myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2023.107693_bb0640","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.2147\/IJN.S321329","article-title":"Recent advances and challenges in gene delivery mediated by polyester-based nanoparticles","volume":"16","author":"Piperno","year":"2021","journal-title":"Int. J. Nanomedicine"},{"issue":"16","key":"10.1016\/j.ymgme.2023.107693_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168537","article-title":"Nanotechnology-based strategies to overcome current barriers in gene delivery","volume":"22","author":"Mir\u00f3n-Barroso","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10322","key":"10.1016\/j.ymgme.2023.107693_bb0650","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107693_bb0655","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic stem- and progenitor-cell gene therapy for hurler syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0660","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s43141-020-00078-y","article-title":"The genome editing revolution: review","volume":"18","author":"Khalil","year":"2020","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0665","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molcel.2016.07.004","article-title":"Methods for optimizing CRISPR-Cas9 genome editing specificity","volume":"63","author":"Tycko","year":"2016","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106968","article-title":"The landscape of CRISPR\/Cas9 for inborn errors of metabolism","volume":"138","author":"Leal","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0675","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40259-023-00610-9","article-title":"Base editing and prime editing: potential therapeutic options for rare and common diseases","volume":"37","author":"Testa","year":"2023","journal-title":"BioDrugs."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107693_bb0680","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/hep.31570","article-title":"Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia","volume":"73","author":"Chandler","year":"2021","journal-title":"Hepatology."},{"issue":"7534","key":"10.1016\/j.ymgme.2023.107693_bb0685","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature13864","article-title":"Promoterless gene targeting without nucleases ameliorates haemophilia B in mice","volume":"517","author":"Barzel","year":"2015","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107693_bb0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233373","article-title":"Molecular characterization of precise in vivo targeted gene integration in human cells using AAVHSC15","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ymgme.2023.107693_bb0695","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0700","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymgme.2022.07.006","article-title":"RNA solutions to treat inborn errors of metabolism","volume":"136","author":"Martinez-Pizarro","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107693_bb0705","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","article-title":"Messenger RNA therapy for rare genetic metabolic diseases","volume":"68","author":"Berraondo","year":"2019","journal-title":"Gut."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0710","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0715","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"17","key":"10.1016\/j.ymgme.2023.107693_bb0720","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0725","first-page":"194","article-title":"Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0730","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of Patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0735","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic. Acid Ther."},{"issue":"13","key":"10.1016\/j.ymgme.2023.107693_bb0740","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0745","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107693_bb0750","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10545-017-0018-6","article-title":"Role of miRNAs in human disease and inborn errors of metabolism","volume":"40","author":"Rivera-Barahona","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107693_bb0755","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26216530","article-title":"RNA activation-a novel approach to therapeutically upregulate gene transcription","volume":"26","author":"Tan","year":"2021","journal-title":"Molecules."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107693_bb0760","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2022.01.004","article-title":"Importance of the long non-coding RNA (lncRNA) transcript HULC for the regulation of phenylalanine hydroxylase and treatment of phenylketonuria","volume":"135","author":"Lin","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"23","key":"10.1016\/j.ymgme.2023.107693_bb0765","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","article-title":"In utero enzyme-replacement therapy for infantile-onset Pompe\u2019s disease","volume":"387","author":"Cohen","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107693_bb0770","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molmed.2021.05.007","article-title":"In utero gene therapy: progress and challenges","volume":"27","author":"Bose","year":"2021","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107693_bb0775","article-title":"Intrauterine fetal gene therapy: is that the future and is that future now?","volume":"14","author":"Peddi","year":"2022","journal-title":"Cureus."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0780","article-title":"Development of synthetic biotics as treatment for human diseases","volume":"7","author":"Brennan","year":"2021","journal-title":"Synth. Biol. (Oxf)."},{"issue":"475","key":"10.1016\/j.ymgme.2023.107693_bb0785","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7975","article-title":"An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans","volume":"11","author":"Kurtz","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0790","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/cer-2017-0068","article-title":"Gene therapy: evidence, value and affordability in the US health care system","volume":"7","author":"Hampson","year":"2018","journal-title":"J. Comp. Eff. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107693_bb0795","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.c.32016","article-title":"Scaling genetic resources: new paradigms for diagnosis and treatment of rare genetic disease","volume":"193","author":"Vockley","year":"2023","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223003232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223003232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T17:14:51Z","timestamp":1735233291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223003232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":154,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1096719223003232"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107693","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The treatment of biochemical genetic diseases: From substrate reduction to nucleic acid therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107693"}}